Vegard Torp Lien*a,
Margrethe Konstanse Kristiansena,
Solveig Pettersenb,
Mads Haugland Haugenb,
Stefan Krausscd,
Dag Erlend Olbergae,
Jo Waalercd and
Jo Klavenessa
aDepartment of Pharmacy, University of Oslo, Oslo, Norway. E-mail: v.t.lien@farmasi.uio.no
bDepartment of Tumor Biology, Institute for Cancer Research, OUS Radiumhospitalet, Oslo, Norway
cHybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway
dDepartment of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
eNorsk Medisinsk Syklotronsenter AS, OUS Rikshospitalet, Oslo, Norway
First published on 31st January 2020
Correction for ‘Towards dual inhibitors of the MET kinase and WNT signaling pathway; design, synthesis and biological evaluation’ by Vegard Torp Lien et al., RSC Adv., 2019, 9, 37092–37100.
In addition, the authors regret the omission of the following funding acknowledgments in the original article: MHH was supported by South-Eastern Norway Regional Health Authority (grant No. 2019081) and SP from the Norwegian Cancer Society (grant No. 190257-2017). J. W. and S. K. were supported by the Research Council of Norway (grant No. 262613, 267639), by South-Eastern Norway Regional Health Authority (grant No. 16/00528-9, 15/00779-2, 2015012 and 2019090) and from the Norwegian Cancer Society (grant No. 5803958).
The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.
This journal is © The Royal Society of Chemistry 2020 |